Clinical Study of Gastric Cancer, Colorectal Cancer and Bladder Cancer Based on Liquid Biopsy
Clinical Study of Gastric Cancer, Colorectal Cancer and Bladder Cancer Based on Liquid Biopsy
Gastric cancer and colorectal cancer are common gastrointestinal malignancies in the
 world.Early cancer generally has no obvious symptoms. Endoscopy is the "gold standard"for the
 diagnosis of gastric cancer and colorectal cancer.gastric cancer and colorectal cancer
 treatment mainly includes surgery and medication.Compared with traditional diagnosis and
 treatment methods, the application of gene detection technology, especially high-throughput
 sequencing technology (NGS) in tumor diagnosis and treatment, performs multi-dimensional and
 multi-target detection of cancer-related genes, which can quickly and accurately determine
 the target gene mutations Morphology and expression differences, so as to provide
 personalized guidance to patients in terms of medication, treatment or prognosis evaluation,
 which can save a lot of time and treatment costs, and improve the overall treatment effect
 and patient quality of life.

 Cystoscopy and biopsy sampling pathological testing are the gold standard for bladder cancer
 diagnosis, and have been widely used in clinical diagnosis and prognosis judgment. However,
 cystoscopy is cumbersome, expensive, and often causes pain to the patients under test. At
 present, the main clinical non-invasive detection technique for bladder cancer is still the
 cytological examination of urinary tract bladder cells in urine, and its sensitivity and
 specificity are not good, especially for the diagnosis of early lower grade bladder
 cancer.For bladder cancer, tumor tissue (puncture biopsy or surgical resection) DNA, urine
 ctDNA, urinary tract exfoliated cell DNA and peripheral blood ctDNA can be used for genetic
 testing, but the consistency of the genetic testing results of these four types of samples
 has not been verified, especially There is no systematic evaluation of the guidance effect of
 non-invasive gene detection of free tumor DNA and urinary tract shed cell DNA in the
 diagnosis and treatment of bladder cancer.The corresponding relationship between the
 significant mutation genes contained in the DNA derived from bladder urinary tract cancer and
 the various types and stages of bladder cancer is not clear.
Inclusion Criteria:

 -  Patients who are scheduled for gastric tumor, colorectal tumor or bladder tumor
 resection Signed informed consent

 Exclusion Criteria:

 -  the vital signs are not stable unconscious unwilling to cooperate